Loading
companiesCompany
Frontier Medicines
Chemoproteomics company with FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, in phase 1/2.
Overview
Frontier Medicines, based in South San Francisco, is a chemoproteomics company whose FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, is in phase 1/2. FMC-376 covalently targets GTP-bound and GDP-bound KRAS G12C and is designed to overcome the adaptive receptor tyrosine kinase feedback that limits first-generation G12C drugs; the PROSPER phase 1/2 trial, NCT06244771, is recruiting with primary completion estimated for October 2027. OnCo links it to non-small-cell lung, colorectal and pancreatic cancer, to KRAS and RAS inhibitors, to KRAS as a target and the MAPK pathway, to the bottleneck of undruggable drivers, and to ideas on covalent chemistry for RAS mutations and an open map of which proteins any drug can bind. Whether dual-state inhibition delays resistance in patients is the question PROSPER will answer. The KRAS target page carries the field.
Similar pages
- CompanyQuanta Therapeutics
Shares Covalent chemistry for the RAS mutations that still have no drug, KRAS & RAS inhibitors, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK).
- TreatmentMRTX1133
Shares Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK).
- TreatmentElironrasib
Shares Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK).
- TrialKRYSTAL-12
Shares Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, The undruggable drivers, KRAS.
- CompanyKumquat Biosciences
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, The undruggable drivers, KRAS, Pancreatic ductal adenocarcinoma.
- TargetSHP2 (PTPN11)
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.
- TrialStudy of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.